1-10 of 10
cytokine release syndrome
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Clinical Trials & Observations
Martina Pennisi, Miriam Sanchez-Escamilla, Jessica R. Flynn, Roni Shouval, Ana Alarcon Tomas, Mari Lynn Silverberg, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Sean M. Devlin, Claudia Diamonte, Sergio Giralt, Elizabeth F. Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Josel Ruiz, Bianca Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Jae H. Park, Lucrecia Yanez San Segundo, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3397–3406.
https://doi.org/10.1182/bloodadvances.2020003885
Published: 2021
Includes: Supplemental data
Journal Articles

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Peter G. Miller, Adam S. Sperling, Elliott J. Brea, Mark B. Leick, Geoffrey G. Fell, Max Jan, Satyen H. Gohil, Yu-Tzu Tai, Nikhil C. Munshi, Catherine J. Wu, Donna S. Neuberg, Marcela V. Maus, Caron Jacobson, Christopher J. Gibson, Benjamin L. Ebert
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2982–2986.
https://doi.org/10.1182/bloodadvances.2021004554
Published: 2021
Includes: Supplemental data
Journal Articles

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Jeremy S. Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Andy Nguyen, Sophie Snyder, November McGarvey, Matthew Gitlin, Corey Pelletier, Monika P. Jun
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1695–1705.
https://doi.org/10.1182/bloodadvances.2020003531
Published: 2021
Journal Articles

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Clinical Trials & Observations
Tania Jain, Andrea Knezevic, Martina Pennisi, Yunxin Chen, Josel D. Ruiz, Terence J. Purdon, Sean M. Devlin, Melody Smith, Gunjan L. Shah, Elizabeth Halton, Claudia Diamonte, Michael Scordo, Craig S. Sauter, Elena Mead, Bianca D. Santomasso, M. Lia Palomba, Connie W. Batlevi, Molly A. Maloy, Sergio Giralt, Eric Smith, Renier Brentjens, Jae H. Park, Miguel-Angel Perales, Sham Mailankody
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3776–3787.
https://doi.org/10.1182/bloodadvances.2020002509
Published: 2020
Includes: Supplemental data
Journal Articles

Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study

Clinical Trials & Observations
Filippo Milano, Jonathan A. Gutman, H. Joachim Deeg, Eneida R. Nemecek, Joachim Baumgart, Laurel Thur, Ann Dahlberg, Rachel B. Salit, Corinne Summers, Frederick R. Appelbaum, Colleen Delaney
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3302–3310.
https://doi.org/10.1182/bloodadvances.2020002222
Published: 2020
Includes: Supplemental data
Journal Articles

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James E. Signorovitch, Vadim V. Romanov, Frederick L. Locke, David G. Maloney
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1432–1439.
https://doi.org/10.1182/bloodadvances.2019001304
Published: 2020
Includes: Supplemental data
Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3473–3480.
https://doi.org/10.1182/bloodadvances.2019000370
Published: 2019
Journal Articles

“Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

Clinical Trials & Observations
Ifigeneia Tzannou, Ayumi Watanabe, Swati Naik, Rachel Daum, Manik Kuvalekar, Kathryn S. Leung, Caridad Martinez, Ghadir Sasa, Mengfen Wu, Adrian P. Gee, Robert A. Krance, Stephen Gottschalk, Helen E. Heslop, Bilal Omer
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2571–2580.
https://doi.org/10.1182/bloodadvances.2019000371
Published: 2019
Includes: Supplemental data
Journal Articles

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Clinical Trials & Observations
Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1970–1980.
https://doi.org/10.1182/bloodadvances.2018028332
Published: 2019
Includes: Supplemental data
Journal Articles

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Clinical Trials & Observations
Tania Jain, Mark R. Litzow
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3393–3403.
https://doi.org/10.1182/bloodadvances.2018020198
Published: 2018